RGEN Quote, Financials, Valuation and Earnings

908 Devices has a net margin of 3.45% compared to Repligen's net margin of -103.33%. Repligen's return on equity of -1.16% beat 908 Devices's return on equity of -12.31%.

Repligen has a consensus price target of $180.82, signalling upside risk potential of 38.89%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -20.75%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

Repligen has a beta of 1.110, which suggesting that the stock is 10.976% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than 908 Devices quarterly revenues of $11.8M. Repligen's net income of $5.8M is lower than 908 Devices's net income of $43.6M. Notably, Repligen's price-to-earnings ratio is 633.44x while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.26x versus 3.93x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies has a net margin of 3.45% compared to Repligen's net margin of 11.6%. Repligen's return on equity of -1.16% beat UFP Technologies's return on equity of 19.38%.

Repligen has a consensus price target of $180.82, signalling upside risk potential of 38.89%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 28.24%. Given that Repligen has higher upside potential than UFP Technologies, analysts believe Repligen is more attractive than UFP Technologies.

Repligen has a beta of 1.110, which suggesting that the stock is 10.976% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.208%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than UFP Technologies quarterly revenues of $148.1M. Repligen's net income of $5.8M is lower than UFP Technologies's net income of $17.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while UFP Technologies's PE ratio is 29.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.26x versus 3.45x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 3.45% compared to Repligen's net margin of -2201.34%. Repligen's return on equity of -1.16% beat VolitionRX's return on equity of --.

Repligen has a consensus price target of $180.82, signalling upside risk potential of 38.89%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 340.32%. Given that VolitionRX has higher upside potential than Repligen, analysts believe VolitionRX is more attractive than Repligen.

Repligen has a beta of 1.110, which suggesting that the stock is 10.976% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than VolitionRX quarterly revenues of $246.4K. Repligen's net income of $5.8M is higher than VolitionRX's net income of -$5.4M. Notably, Repligen's price-to-earnings ratio is 633.44x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.26x versus 46.02x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 3.45% compared to Repligen's net margin of 0.18%. Repligen's return on equity of -1.16% beat Xtant Medical Holdings's return on equity of -26.62%.

Repligen has a consensus price target of $180.82, signalling upside risk potential of 38.89%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 167.18%. Given that Xtant Medical Holdings has higher upside potential than Repligen, analysts believe Xtant Medical Holdings is more attractive than Repligen.

Repligen has a beta of 1.110, which suggesting that the stock is 10.976% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Repligen quarterly revenues are $169.2M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Repligen's net income of $5.8M is higher than Xtant Medical Holdings's net income of $58K. Notably, Repligen's price-to-earnings ratio is 633.44x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 11.26x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.